AbCellera starts Phase 2 dosing for ABCL635

AbCellera Biologics Inc. filed an update describing two investor-focused developments.

Rhea-AI Filing Summary

AbCellera Biologics Inc. filed an update describing two investor-focused developments. The company has begun dosing the first patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, signaling that this experimental therapy has advanced to the next stage of human testing.

AbCellera also posted an updated corporate presentation on its investor website, which it may use in future communications and conferences. Both the press release about ABCL635 and the new presentation are furnished as exhibits and are not treated as filed financial statements under securities law.

Insights

Biotech and clinical development analyst

AbCellera advances ABCL635 into Phase 2 and refreshes investor materials.

AbCellera reports that first patients have now been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. Moving into Phase 2 typically means the program is progressing beyond initial safety and dose-finding work toward a greater focus on evaluating effectiveness in patients, although specific trial design details are not provided here.

The company also furnished an updated corporate presentation on its investor website, indicating refreshed disclosure around its pipeline and strategy. The information is expressly furnished, not filed, which limits its use in certain legal contexts. The actual impact for shareholders will depend on future clinical data from ABCL635 and additional detail in the accompanying press release and presentation.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AbCellera (ABCL) disclose in its latest 8-K filing?

AbCellera Biologics Inc. disclosed that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635 and that it has posted an updated corporate presentation on its investor website.

What is the status of AbCellera's ABCL635 clinical trial?

AbCellera stated that first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, indicating that the program has progressed into a more advanced stage of testing.

Did AbCellera (ABCL) provide new investor materials with this 8-K?

Yes. AbCellera furnished a new corporate presentation, dated January 14, 2026, which it posted to its investor website and may use in future communications or conferences.

Are the ABCL635 update and presentation considered filed financial information?

No. AbCellera specified that the information in Item 7.01, including the press release and corporate presentation exhibits, is being furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Which exhibits were included in AbCellera's January 2026 8-K?

The exhibits include a press release about ABCL635 dated January 12, 2026 (Exhibit 99.1), a corporate presentation dated January 14, 2026 (Exhibit 99.2), and a cover page interactive data file (Exhibit 104).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 05:09 PM Learn about SEC filing dates

0001703057falseVancouverBC00017030572026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________

FORM 8-K

__________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 12, 2026

__________________________________________

AbCellera Biologics Inc.

(Exact name of registrant as specified in its charter)

__________________________________________

British Columbia			001-39781			Not Applicable
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

150 W 4th Avenue Vancouver, BC			V5Y 1G6
(Address of registrant’s principal executive office)			(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common shares			ABCL			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 7.01    Regulation FD

On January 12, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. A copy of the press release is furnished herewith as Exhibit 99.1.

On January 14, 2026, the Company posted an updated corporate presentation to its website at https://investors.abcellera.com. The Company may use the corporate presentation from time to time in communications or conferences. A copy of the corporate presentation is furnished as Exhibit 99.2.

The information in Item 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01    Financial Statements and Exhibits

(d)Exhibits

Exhibit No.						Description
99.1						Press Release issued by AbCellera Biologics Inc. on January 12, 2026.
99.2						AbCellera Biologics Inc. Corporate Presentation, dated January 14, 2026.
104						Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 14, 2026			ABCELLERA BIOLOGICS INC.
			By:			/s/ Carl L. G. Hansen
						Carl L. G. Hansen, Ph.D.
						Chief Executive Officer and Director (Principal Executive Officer)